Calamos Global Opportunities' 17.7% Q2: Earnings Momentum Everywhere, Except One Name

The headline on Calamos Global Opportunities' second-quarter letter is a beat: the fund returned 17.73% before fees (17.53% net of fees) in the three months through June 30, against 15.06% for the MSCI All Country World Index — roughly 2.7 points of relative gain in a single quarter for a strategy that markets itself as a way to manage downside. More interesting than the number is the explanation attached to it, because it is a testable claim rather than a victory lap: global markets have been "driven by earnings improvements and upward earnings revisions — not unsupported price momentum." For anyone who treats a factor argument as something you check rather than take on faith, that is an invitation.

The engine

The portfolio makes the bet easy to inspect. Five of the fund's ten largest positions at June 30 were chip companies or the equipment that builds them — Nvidia at 5.0% of assets, Taiwan Semiconductor at 4.6%, Samsung at 4.2%, Intel at 2.3%, and ASML at 2.1% — nearly 18% of the fund in one vertical, and information technology alone came to 34.3% of assets. The quarter's wind blew straight through that block: the benchmark's technology sector rose 39.2%, emerging markets returned 24.15%, and Korea — where Samsung lives — rose 87.6%. This is what a "the market is paying for growth" quarter looks like when you happen to be holding the growth.

The check

Run the growth-and-valuation stack on that sleeve and the thesis mostly holds. Nvidia earns arguably the best growth-and-profitability profile in the whole set — revenue up 83% year over year, gross margin north of 70%, return on invested capital (the profit a company squeezes from the capital it deploys) near 87% — and it trades near 26x trailing earnings. Against AMD at 122x and ASML at 55x, the biggest and fastest-growing name carries one of the cheaper multiples. Taiwan Semiconductor: 24% revenue growth, roughly 30% ROIC, near 32x earnings with a price-to-growth ratio (PEG) below 0.7 — cheaper on a growth-adjusted basis than the fund it anchors. ASML is the reversal — solid 17% growth at a demanding 55x. Even the value seat fits the mold: Alphabet, at 4.4% of assets and around 17x trailing earnings with 20% revenue growth, is the fund's cheap-quality ballast (recent outsized reported earnings flatter that multiple, and free cash flow fell 20% as the company spent more than $130 billion on AI infrastructure).

The revisions layer — the part of the letter's argument that actually does the work — also checks out. Nvidia, Taiwan Semiconductor, and Eli Lilly each reported quarters that beat both the standing estimate and a rising staircase of estimates before it: Lilly printed $8.38 against a $6.01 consensus, Nvidia $1.05 against $1.01, Taiwan Semi $4.22 against $3.81. That is the mechanism behind the claim, and it is present in the data, not just the prose. The fund's aggregate math is consistent with it: on Calamos's own profile it carries an earnings multiple of 25.9x against the benchmark's 22.3x and sells near 3.6x sales versus 2.6x — a real premium — yet its PEG lands at 1.3x versus 1.8x, and its ROIC of 25.3% matches the benchmark's 24.8%. On the trade-off that matters — do you actually get paid for the premium? — the answer, for now, is yes.

The name that doesn't fit

Then there is the holding that does not fit the story the letter tells. Intel, 2.3% of the fund, is its most price-momentum-like position: trailing operating margin near -9%, return on invested capital below zero, no real trailing earnings to hang a multiple on — a D-grade profitability card inside a portfolio that claims to buy upgrades to established earners. To give the managers their due, the direction is genuinely better: second-quarter revenue rose about 19% sequentially and adjusted earnings turned positive, so this is the "improving report card," not a broken company. But the external cross-check is lukewarm — AInvest's aggregate signal labels Intel Hold, not Buy — and the tape has already turned against the run: the stock sits near $88, below its 50-day average of about $106, with an RSI in the high 30s after its long climb. The thesis says the fund buys earnings revisions. Intel is the one top-ten position where what you are actually holding is the price-momentum trade the letter disclaims.

The sleeve that costs in rallies

The drag inside those 17.7 points came from the part of the portfolio built to lose rallies. Utilities — 6.8% of assets against 2.5% in the benchmark — lagged, real estate dragged, and so did the two convertible positions, Iberdrola Finanzas and Robinhood at 2.1% and 2.0% of assets. That is the machinery behind the strategy's "lower-volatility" pitch: a convertible is a bond that can turn into stock, and these carry a median conversion premium around 25% with duration near 1.6 years — meaning they participate in an up market but sit close enough to a bond to catch you on the way down. Their job is exactly to cost money in a quarter like this one and pay it back in the next drawdown. Healthcare, the other big overweight (12.5% vs 8.3%), is the defensive-growth sleeve, and the reason Eli Lilly — 50% revenue growth at around 42x — earns its keep.

What comes next

The honest limitation of the letter's argument: a 39% technology quarter is not pure fundamentals. Part of it was the market paying more for the same earnings — precisely the "unsupported price momentum" the managers disclaim — and that slice can reverse without any company doing anything wrong. It has already begun to: by late August the fund's year-to-date gain had cooled to about 15.4% — roughly two and a half points below what it had banked by the end of June — as momentum indicators on the AI names came off the boil.

For an investor weighing whether this fund belongs in a portfolio, the frame that fits is a barbell, not a diversified global wrapper. The return engine is the growth block — upward-revision names with defensible multiples (Nvidia, Taiwan Semi, Lilly) plus a cheap-quality anchor (Alphabet) — and it is what earned the quarter. The hedge sleeve is the insurance: convertibles with bond floors, an overweight to utilities and defensive pharma that costs in rallies and softens drawdowns. What would change the reading is the revisions cycle stalling: if guidance at the top names stops climbing, the expensive end of the book (ASML at 55x, Lilly at 42x) is where the air comes out first. And the single concrete fault line right now is Intel's 50-day average — the one position where the factor stack and the narrative disagree, and the easiest way to tell whether the fund is still being paid for earnings momentum or quietly drifting into the trade it says it does not make.